Krolicki and collaborators demonstrated the safety and feasibility of radionuclide therapy with 225Ac-DOTA-substance P in a group of 21 patients with recurrent glioma (1 patient with WHO-grade-II glioma, 8 patients with WHO-grade-III glioma, 12 patients with WHO-grade-IV glioma). The gene discussed is TAC1; the disease is central nervous system cancer.